Date Added: 27/06/2017
Date Updated: 27/06/2017
Islet cell replacement therapy for insulin-dependent diabetes
Specialties: Endocrine, nutritional and metabolic
Technology Type: Procedures
Stage of development: Investigational - phase III
Stage of EAA: Assessment Complete
ViaCyte’s PEC-Direct and PEC-Encap (VC-01) products offer a potential “functional cure” for patients with type 1 diabetes and insulin-dependent type 2 diabetes.
Using human pancreatic progenitor cells (PEC-01) created in the lab, both the PEC-Direct and the PEC-Encap products are implanted into patients, where they mature into functional pancreatic islet tissue that includes glucose-responsive insulin-producing beta cells.
The PEC-Encap product offers the additional benefit of an encapsulation device designed to protect the cells from the immune system.
The current evidence is limited to phase I and II human trials evaluating the safety of the PEC-Encap product and pre-clinical study of the PEC-Direct product.
There are insufficient data about efficacy in humans, adverse effects, and the length of time the product can remain safely implanted and functional.
The future cost of ViaCyte’s products is unknown.
Keywords: Type 1 diabetes, Type 2 diabetes, ViaCyte, islet cell transplantation